Taysha Gene Therapies (TSHA) Non-Current Assets (2020 - 2026)

Taysha Gene Therapies (TSHA) has 7 years of Non-Current Assets data on file, last reported at $18.1 million in Q1 2026.

• For the quarter ending Q1 2026, Non-Current Assets rose 2.53% year-over-year to $18.1 million; the trailing twelve-month figure through Mar 2026 stood at $70.4 million (down 7.88% YoY), and the FY2025 full-year result was $18.7 million, up 2.41% from the prior year.
• Non-Current Assets slipped to $18.1 million in Q1 2026, from $18.7 million in the prior quarter.
• In the past five years, Non-Current Assets ranged from a high of $68.5 million in Q3 2022 to a low of $16.6 million in Q3 2025.
• A 5-year average of $29.2 million and a median of $22.4 million in 2024 frame the typical range for Non-Current Assets.
• Across the five-year window, Non-Current Assets jumped 1746.41% in 2022 and slumped 65.0% in 2023, its largest moves.
• Tracing TSHA's Non-Current Assets over 5 years: stood at $29.9 million in 2022, then decreased by 23.43% to $22.9 million in 2023, then declined by 20.25% to $18.2 million in 2024, then grew by 2.41% to $18.7 million in 2025, then declined by 3.06% to $18.1 million in 2026.
• Business Quant data shows TSHA's Non-Current Assets at $18.1 million in Q1 2026, $18.7 million in Q4 2025, and $16.6 million in Q3 2025.